

Appl. No. 09/993,300 Amdt. dated Reply to Office action of June 14, 2005

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

Claim 1. (currently amended) An isolated biopolymer marker ~~selected from the group~~ consisting of SEQ ID NO:1 ~~[[and]] or~~ consisting of SEQ ID NO:2.

Claims 2-38. (cancelled).

*Insert*  
Claim <sup>2</sup>~~39~~. (withdrawn-currently amended) A method for determining <sup>in a patient sample</sup> ~~the~~ presence of ~~a~~ <sup>which is linked to Type II diabetes</sup> ~~an isolated biopolymer marker~~ selected from the group consisting of SEQ ID NO:1 ~~[[and]] or~~ consisting of SEQ ID NO:2 <sup>comprising:</sup>

(a) obtaining a sample from a patient;

(b) conducting mass spectrometric analysis on said sample in a manner effective to maximize analysis of peptide fragments contained therein and comparing mass spectrum profiles of said isolated biopolymer marker ~~selected from the group~~ consisting of SEQ ID NO:1 ~~[[and]] or~~ consisting of SEQ ID NO:2 to mass spectrum profiles of peptides obtained and analyzed from said sample; and

Appl. No. 09/993,300 Amdt. dated Reply to Office action of June 14, 2005

(c) confirming the presence of said ~~isolated~~ biopolymer marker ~~selected from the group~~ consisting of SEQ ID NO:1 ~~[[and]]~~ or consisting of SEQ ID NO:2 in said sample displaying a peak profile at about 1624 daltons or at about 1552 daltons in said mass spectrum profile;

wherein the presence of said ~~isolated~~ biopolymer marker ~~selected from the group~~ consisting of SEQ ID NO:1 ~~[[and]]~~ or consisting of SEQ ID NO:2 is indicative of a link to Type II diabetes.

Claim <sup>3</sup>40. (withdrawn) The method of claim <sup>2</sup>39, wherein said sample is an unfractionated body fluid or tissue sample.

Claim <sup>4</sup>41. (withdrawn) The method of claim <sup>3</sup>39, wherein said sample is selected from the group consisting of blood, blood products, urine, saliva, cerebrospinal fluid, and lymph.

Claim <sup>5</sup>42. (withdrawn) The method of claim <sup>2</sup>39, wherein said mass spectrometric analysis is selected from the group consisting of Surface Enhanced Laser Desorption Ionization (SELDI) mass spectrometry (MS), Maldi Qq TOF, MS/MS, TOF-TOF, ESI-Q-TOF and ION-TRAP.

Appl. No. 09/993,300 Amdt. dated Reply to Office action of June 14, 2005 2

Claim 43.6 (withdrawn) The method of claim 39, wherein said patient is a human.

Claim 44.7 (withdrawn-currently amended) A kit for determining the presence of a ~~an isolated biopolymer marker selected from the group~~ consisting of SEQ ID NO:1 ~~[[and]]~~ or consisting of SEQ ID NO:2 comprising: (a) a ~~an isolated biopolymer marker selected from the group~~ consisting of SEQ ID NO:1 ~~[[and]]~~ or consisting of SEQ ID NO:2, and (b) an antibody that binds to said ~~isolated~~ biopolymer marker ~~selected from the group~~ consisting of SEQ ID NO:1 ~~[[and]]~~ or consisting of SEQ ID NO:2 in a sample from a patient.

Claim 45.8 (withdrawn) The kit of claim 44, wherein said antibody is immobilized on a solid support.

Claim 46.9 (withdrawn) The kit of claim 44, wherein said antibody is labeled.